HCPLive Network

Heart Failure Total Cost Estimated at $70 Billion by 2030

THURSDAY, April 25 (HealthDay News) -- The impact of heart failure is likely to increase, with more than eight million U.S. adults anticipated to have heart failure by 2030, at an estimated total cost of $70 billion, according to a study published online April 24 in Circulation: Heart Failure.

Paul A. Heidenreich, MD, from Stanford University, in California, and colleagues estimated the epidemiology and future costs of heart failure from 2012 to 2030, based on a model that assumes heart failure prevalence will remain constant and that the costs and technological innovation will continue to increase at the same rate.

The researchers projected that more than eight million people in the Unites States will have heart failure by 2030. The direct costs of medications are expected to increase from $21 billion in 2012 to $53 billion in 2030. The estimated total costs, including indirect costs, are expected to increase from $31 billion to $70 billion. Assuming all costs of cardiac care for patients with heart failure are attributable to heart failure, and not to comorbid conditions, the cost estimates projected for 2030 would be $160 billion in direct costs.

"Assuming continuation in present practice patterns, the cost of heart failure is projected to increase markedly over the next 18 years based on demographic changes in the population," the authors write. "The cost would be substantial, with each U.S. adult, on average, paying $244 annually by 2030 to care for the 10 million patients with heart failure."

Several authors disclosed financial ties to the pharmaceutical and medical device industries.

Abstract
Full Text

Copyright © 2013 HealthDay. All rights reserved.

Further Reading
Results of a randomized controlled trial demonstrate that a long-term, supervised, moderate-intensity exercise training program for chronic heart failure patients can produce improvements in hospital readmission and survival rates.
Sodium and water restriction are unnecessary in patients hospitalized for acute decompensated heart failure (ADHF).
The US Food and Drug Administration has awarded “breakthrough therapy” status to a synthetic copy of a naturally occurring human hormone for the treatment of acute heart failure (AHF), drug developer Novartis announced today.
Cardiac rehabilitation (CR) exercise training and chronic heart failure self-care counseling provide significant clinical benefits to individuals with stable chronic heart failure.
For adults with previous myocardial infarction, high-dose oral vitamin and mineral supplementation is not associated with a reduction in cardiac events, according to a study presented at ACC.13.
Approved by the FDA nearly four years ago, Otsuka Group’s once-daily Samsca (tolvaptan tablets) is indicated to raise serum sodium levels in nonurgent patients with hyponatremia.
For patients with acute exacerbations of chronic obstructive pulmonary disease or community-acquired pneumonia, use of clarithromycin correlates with increased risk of cardiovascular events, according to a study published online March 22 in BMJ.
More Reading